Donanemab Biosimilar - Research Grade

Human

APPï؟½

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P05067

Blue ice

Amyloid precursor protein (APP) and its proteolytic amyloid-beta fragments are central to the pathology studied across Alzheimer's disease research. Our anti-human APP recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of donanemab, offered exclusively for research use only (RUO). Manufactured under rigorous in vivo standards, this ultra-pure, low-endotoxin formulation ships in scalable milligram (mg) to gram (g) quantities to support heavy-usage, high-throughput laboratories. Researchers can deploy it as a consistent reference reagent and active tool spanning in vitro plaque-binding assays, neurodegeneration model work, and in vivo studies of amyloid clearance, as well as broader biologics characterization.

Amyloid-beta precursor protein, amyloid precursor protein

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.